Rheumatoid arthritis - adalimumab, etanercept and infliximab
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
Summary
This guidance recommends adalimumab, etanercept and infliximab as possible treatments for people with rheumatoid arthritis who: have already tried methotrexate and another disease-modifying anti-rheumatic drug (DMARD), and have 'active' rheumatoid arthritis, as assessed by a rheumatologist on ...
This guidance partially replaces TA36 'Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis' issued in March 2002. This review and re-appraisal has additionally included adalimumab for the treatment of rheumatoid arthritis, and has taken into account changes in the marketing authorisations for infliximab and etanercept.
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in September 2010
About this guidance
Technology appraisals TA130
Issued: October 2007
How this guidance was produced